Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: TSE:INO
- CUSIP: N/A
- Web: www.inovio.com/
- Trailing P/E Ratio: N/A
- P/E Growth: N/A
- Net Margins: -222.49%
- Return on Equity: -81.23%
- Return on Assets: -56.63%
Frequently Asked Questions for Inovalis Real Estate Investment Trust (TSE:INO)
What is Inovalis Real Estate Investment Trust's stock symbol?
Inovalis Real Estate Investment Trust trades on the Tornton Stock Exchange (TSX) under the ticker symbol "INO."
How often does Inovalis Real Estate Investment Trust pay dividends? What is the dividend yield for Inovalis Real Estate Investment Trust?
Inovalis Real Estate Investment Trust declared a monthly dividend on Friday, June 23rd. Investors of record on Friday, June 30th will be given a dividend of 0.069 per share on Monday, July 17th. This represents a $0.83 annualized dividend and a dividend yield of Infinity. The ex-dividend date is Wednesday, June 28th. View Inovalis Real Estate Investment Trust's Dividend History.
How were Inovalis Real Estate Investment Trust's earnings last quarter?
Inovalis Real Estate Investment Trust (TSE:INO) issued its earnings results on Friday, August, 15th. The company reported $0.22 earnings per share for the quarter, meeting the consensus estimate of $0.22. The firm earned $4.66 million during the quarter, compared to analyst estimates of $4.63 million. Inovalis Real Estate Investment Trust had a negative net margin of 222.49% and a negative return on equity of 81.23%. View Inovalis Real Estate Investment Trust's Earnings History.
Who are some of Inovalis Real Estate Investment Trust's key competitors?
Some companies that are related to Inovalis Real Estate Investment Trust include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), Icon Plc (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories International (CRL), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Exact Sciences Corporation (EXAS), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR) and Puma Biotechnology (PBYI).
Who are Inovalis Real Estate Investment Trust's key executives?
Inovalis Real Estate Investment Trust's management team includes the folowing people:
- Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director
- Peter D. Kies, Chief Financial Officer
- Niranjan Y. Sardesai Ph.D., Chief Operating Officer
- Mark L. Bagarazzi M.D., Chief Medical Officer
- Avtar S. Dhillon M.D., Non-Executive Chairman of the Board
- George W. Bickerstaff III, Director
- David B. Weiner, Director
- Simon X. Benito, Independent Director
- Angel Cabrera Ph.D., Independent Director
How do I buy Inovalis Real Estate Investment Trust stock?
MarketBeat Community Rating for Inovalis Real Estate Investment Trust (TSE INO)MarketBeat's community ratings are surveys of what our community members think about Inovalis Real Estate Investment Trust and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shares of Inovalis Real Estate Investment Trust and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
Consensus Ratings for Inovalis Real Estate Investment Trust (TSE:INO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Inovalis Real Estate Investment Trust (TSE:INO)
(Data available from 7/25/2015 forward)
|5/25/2016||National Bank Financial||Downgrade||Outperform Market Weight -> Sector Perform Market Weight|
|3/28/2016||Desjardins||Downgrade||Buy -> Hold|
Earnings History for Inovalis Real Estate Investment Trust (TSE:INO)Earnings History by Quarter for Inovalis Real Estate Investment Trust (TSE INO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/15/2014||$0.22||$0.22||$4.63 million||$4.66 million||View||N/A|
|5/7/2014||$0.20||$0.23||$4.63 million||$4.89 million||View||N/A|
Earnings Estimates for Inovalis Real Estate Investment Trust (TSE:INO)
2017 EPS Consensus Estimate: $1.03
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History by Quarter for Inovalis Real Estate Investment Trust (TSE INO)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for Inovalis Real Estate Investment Trust (TSE:INO)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Inovalis Real Estate Investment Trust (TSE:INO)
Latest Headlines for Inovalis Real Estate Investment Trust (TSE:INO)
Inovalis Real Estate Investment Trust (INO) Chart for Tuesday, July, 25, 2017